Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met?

[1]  M. Chung,et al.  Normalization of Left Ventricular Ejection Fraction after Cardiac Resynchronization Therapy Also Normalizes Survival , 2013, Pacing and clinical electrophysiology : PACE.

[2]  A. Kadish,et al.  Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). , 2013, Heart rhythm.

[3]  I. Anand,et al.  Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. , 2013, Journal of cardiac failure.

[4]  L. Shaw,et al.  Association Between Left Ventricular Ejection Fraction Post-Cardiac Resynchronization Treatment and Subsequent Implantable Cardioverter Defibrillator Therapy for Sustained Ventricular Tachyarrhythmias , 2013, Circulation. Arrhythmia and electrophysiology.

[5]  Sharon-Lise Normand,et al.  Characteristics and Outcomes of Patients Receiving New and Replacement Implantable Cardioverter-Defibrillators: Results From the NCDR , 2013, Circulation. Cardiovascular quality and outcomes.

[6]  Eugene Crystal,et al.  Predictors of Short-Term Complications After Implantable Cardioverter-Defibrillator Replacement: Results From the Ontario ICD Database , 2011, Circulation. Arrhythmia and electrophysiology.

[7]  Jeroen J. Bax,et al.  Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. , 2011, Journal of the American College of Cardiology.

[8]  D. Abbey,et al.  Medicare Physician Fee Schedule. , 2023, JAMA.

[9]  M. Chung,et al.  Complication Rates Associated With Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures: Results From the REPLACE Registry , 2010, Circulation.

[10]  I. Piña,et al.  Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. , 2010, Heart rhythm.

[11]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[12]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[13]  M. Josephson,et al.  A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.

[14]  D. Mark,et al.  Prognostic importance of defibrillator shocks in patients with heart failure. , 2008, The New England journal of medicine.

[15]  J. Ornato,et al.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2008, Heart rhythm.

[16]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.

[17]  J. Daubert,et al.  The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. , 2006, European heart journal.

[18]  M. Cheitlin.  Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy , 2007 .

[19]  R. Berger,et al.  Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy? , 2006, Circulation.

[20]  Douglas K Owens,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.

[21]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[22]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[23]  G. Boriani,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2001, European heart journal.

[24]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[25]  J. Rouleau,et al.  Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. , 1996, Journal of the American College of Cardiology.

[26]  S. Connolly,et al.  Standardized Reporting of ICD Patient Outcome: The Report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9–10, 1993 , 1993, Pacing and clinical electrophysiology : PACE.

[27]  D. Sharpe,et al.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. , 1984, Circulation.

[28]  J. Fleiss,et al.  Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.